Active Surveillance for Low-risk Papillary Thyroid Carcinoma-Reply

JAMA Oncol. 2023 May 1;9(5):722-723. doi: 10.1001/jamaoncol.2023.0006.

Authors

Allen S Ho^{1

2}, Wendy L Sacks^{1

3}, Zachary S Zumsteg^{1

4}

Affiliations

¹ Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
² Division of Otolaryngology-Head & Neck Surgery, Department of Surgery, Cedars-Sinai Medical Center, Los Angeles, California.
³ Division of Endocrinology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.
⁴ Department of Radiation Oncology, Cedars-Sinai Medical Center, Los Angeles, California.

PMID: 36862392
DOI: 10.1001/jamaoncol.2023.0006

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Risk
Thyroid Cancer, Papillary
Thyroid Neoplasms* / epidemiology
Thyroid Neoplasms* / therapy
Watchful Waiting*